Influence of AGTR1 and ABCB1 Gene Polymorphism on the Curative Effect of Irbesartan.

Int J Hypertens

Division of Histology and Embryology, Joint Laboratory for Embryonic Development & Prenatal Medicine, Medical College, Jinan University, Guangzhou 510632, China.

Published: November 2022

The interindividual heterogeneity in response to the antihypertensive effect of irbesartan has received considerable attention because of gene polymorphism. In this study, we investigated the new combinational influences of AGTR1 and ABCB1 gene polymorphism on the therapeutic effect of irbesartan among Chinese hypertensive patients. A total of 353 samples including 168 normal people and 185 hypertensive patients were adopted, and genotypes comprise ABCB1 (CC, CT, and TT) and AGTR1 (AA and AC) in this study. The results of multiple linear regression models showed that no statistically significant differences were observed in blood pressure change following irbesartan administration in each genotype from either ABCB1 (CC, CT, and TT) or AGTR1 (AA and AC). However, spline smoothing analysis demonstrated that the blood pressure therapeutic responses of irbesartan presented a noticeable difference among different ABCB1 genotypes when irbesartan doses reached over 300 ng/mL. Eventually, we assumed that the different drug responses of irbesartan among various AGTR1 genotypes were due to the diversity of the irbesartan-conjugated protein, which is responsible for crossing-coupled intracellular G-protein-coupled receptors (GPCRs).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668479PMC
http://dx.doi.org/10.1155/2022/4278675DOI Listing

Publication Analysis

Top Keywords

gene polymorphism
12
agtr1 abcb1
8
abcb1 gene
8
hypertensive patients
8
abcb1 agtr1
8
blood pressure
8
responses irbesartan
8
irbesartan
7
abcb1
5
influence agtr1
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!